Complete financial analysis of MediWound Ltd. (MDWD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MediWound Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ACRES Commercial Realty Corp. (ACR) Income Statement Analysis – Financial Results
- Jiangsu Eazytec Co., Ltd. (688258.SS) Income Statement Analysis – Financial Results
- Kirin Holdings Company, Limited (KNBWY) Income Statement Analysis – Financial Results
- Tian Poh Resources Limited (TPO.AX) Income Statement Analysis – Financial Results
- CompuGroup Medical SE & Co. KGaA (CMPVF) Income Statement Analysis – Financial Results
MediWound Ltd. (MDWD)
About MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.69M | 26.50M | 23.76M | 21.76M | 31.79M | 3.40M | 2.50M | 1.56M | 601.00K | 259.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.11M | 13.33M | 14.99M | 14.22M | 11.85M | 2.09M | 1.58M | 2.16M | 2.52M | 2.79M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.58M | 13.17M | 8.77M | 7.55M | 19.94M | 1.31M | 918.00K | -600.00K | -1.92M | -2.53M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 19.15% | 49.69% | 36.91% | 34.67% | 62.73% | 38.61% | 36.78% | -38.51% | -319.13% | -975.29% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.47M | 10.18M | 10.26M | 7.70M | 4.97M | 4.07M | 5.46M | 7.07M | 6.02M | 5.35M | 3.64M | 1.56M | 3.02M |
| General & Administrative | 8.57M | 8.33M | 6.11M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 4.72M | 1.63M | 1.14M | 1.24M |
| Selling & Marketing | 2.80M | 2.04M | 3.39M | 3.23M | 4.06M | 4.19M | 5.36M | 8.40M | 9.28M | 8.83M | 2.26M | 0.00 | 0.00 |
| SG&A | 11.38M | 10.37M | 9.74M | 8.69M | 9.31M | 7.99M | 9.14M | 12.49M | 13.29M | 13.55M | 3.89M | 1.14M | 1.24M |
| Other Expenses | 24.00K | 958.00K | -710.00K | -144.00K | 1.17M | -751.00K | 56.00K | 66.00K | 59.00K | 49.00K | 57.00K | 33.00K | 24.00K |
| Operating Expenses | 18.87M | 21.51M | 19.99M | 16.39M | 15.45M | 5.27M | 14.61M | 19.56M | 19.31M | 18.90M | 7.58M | 2.73M | 4.29M |
| Cost & Expenses | 33.98M | 34.84M | 34.98M | 30.60M | 27.30M | 7.36M | 16.18M | 21.71M | 21.83M | 21.69M | 7.58M | 2.73M | 4.29M |
| Interest Income | 2.34M | 270.00K | 11.00K | 297.00K | 434.00K | 412.00K | 0.00 | 1.27M | 288.00K | 4.67M | 1.00K | 6.00K | 32.00K |
| Interest Expense | 427.00K | 8.92M | 903.00K | 832.00K | 925.00K | 892.00K | 478.00K | 847.00K | 444.00K | 2.11M | 2.44M | 673.00K | 591.00K |
| Depreciation & Amortization | 1.30M | 1.27M | 1.24M | 1.09M | 1.15M | 577.00K | 567.00K | 589.00K | 503.00K | 492.00K | 336.00K | 267.00K | 196.00K |
| EBITDA | -4.89M | -18.09M | -11.22M | -7.75M | 3.42M | -5.09M | -13.12M | -18.30M | -20.72M | -18.33M | -6.50M | 12.25M | -4.10M |
| EBITDA Ratio | -26.19% | -35.22% | -42.01% | -35.61% | 17.75% | -99.47% | -525.64% | -1,255.84% | -3,448.25% | -6,281.85% | 0.00% | 0.00% | 0.00% |
| Operating Income | -15.29M | -8.35M | -11.22M | -8.84M | 4.49M | -3.96M | -13.69M | -20.16M | -21.23M | -21.43M | -7.58M | -2.73M | -4.29M |
| Operating Income Ratio | -81.83% | -31.50% | -47.22% | -40.62% | 14.13% | -116.44% | -548.36% | -1,293.65% | -3,531.95% | -8,272.97% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.76M | -11.18M | -2.30M | -436.00K | -2.43M | -1.71M | -846.00K | 1.27M | -444.00K | 2.55M | -920.00K | 14.72M | -532.00K |
| Income Before Tax | -6.53M | -19.52M | -13.52M | -9.28M | 2.07M | -5.67M | -14.53M | -18.89M | -21.67M | -18.88M | -8.50M | 11.99M | -4.82M |
| Income Before Tax Ratio | -34.95% | -73.68% | -56.91% | -42.62% | 6.50% | -166.57% | -582.25% | -1,212.13% | -3,605.82% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 185.00K | 78.00K | 27.00K | 325.00K | -1.65M | -9.69M | 8.46M | -1.27M | 861.00K | -2.55M | 7.77M | -13.67M | 1.88M |
| Net Income | -6.72M | -19.60M | -13.55M | -9.60M | 3.72M | -1.06M | -22.15M | -18.89M | -22.09M | -18.88M | -15.35M | 10.94M | -6.17M |
| Net Income Ratio | -35.94% | -73.97% | -57.03% | -44.12% | 11.70% | -31.08% | -887.38% | -1,212.13% | -3,675.21% | -7,287.64% | 0.00% | 0.00% | 0.00% |
| EPS | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| EPS Diluted | -0.75 | -3.93 | -3.48 | -2.47 | 0.96 | -0.27 | -6.64 | -6.05 | -7.13 | -6.65 | -5.28 | 3.76 | -2.12 |
| Weighted Avg Shares Out | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
| Weighted Avg Shares Out (Dil) | 9.01M | 4.99M | 3.89M | 3.89M | 3.88M | 3.87M | 3.33M | 3.12M | 3.10M | 2.84M | 2.91M | 2.91M | 2.91M |
MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q3 2024 Earnings Conference Call November 26, 2024 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - Executive Vice...
MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.24 per share a year ago.
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cas h Runway to Profitability NexoBrid...
MediWound Is A Healthy Investment
MediWound is a long-term buy opportunity with significant upside potential, driven by its innovative wound and lesion care products in a strong, growing industry. Despite current financial struggles, including increased losses and low margins, MediWound's revenue is expected to grow,...
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages Approval Helps Solidify NexoBrid's Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages
MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
MediWound Ltd. (NASDAQ:MDWD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Gaia Shamis - IR, LifeSci Advisors Ofer Gonen - Chief Executive Officer Hani Luxenburg - Chief Financial Officer Barry Wolfenson - EVP of...
MediWound (MDWD) Reports Q2 Loss, Lags Revenue Estimates
MediWound (MDWD) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to earnings of $0.10 per share a year ago.
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
Completed Construction of New NexoBrid ® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx ® Development for Diabetic Foot Ulcer s , Significantly Expanding the Addressable Market ; Phase III Study for Venous Leg Ulcers to Begin in H2 2024...
MediWound (MDWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
MediWound (MDWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports